GlassScriptPhysician profile
Vera Lafosse
NPI 1104265016
$3,125.13
in general payments reported to CMS, 2019-2025
29 companies · $500 in 2025
The $500 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $915 · 2020: $577 · 2021: $786 · 2022: $347 · 2025: $500.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $500.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $500.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $609.66 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $494.26 | 2019-2025 | Airsupra, Farxiga |
| Astellas Pharma US INC | $275.44 | 2019-2021 | |
| Amgen INC. | $269.99 | 2019-2022 | |
| Abbvie INC. | $172.38 | 2020-2025 | |
| Lilly USA, LLC | $143.64 | 2019-2025 | Mounjaro, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $127.45 | 2019-2022 | |
| Amarin Pharma, INC. | $113.96 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $89.52 | 2019-2021 | |
| Optinose US, INC. | $76.01 | 2020-2021 | |
| Glaxosmithkline, LLC. | $75.15 | 2019-2025 | Shingrix, Arexvy |
| Genentech USA, INC. | $72.88 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $65.66 | 2019 | |
| Pfizer INC. | $65.11 | 2019-2025 | |
| Biohaven Pharmaceuticals, INC. | $64.27 | 2021 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $52.29 | 2020 | |
| Abbott Laboratories | $45.97 | 2025 | Freestyle Libre 3 |
| Sanofi-Aventis U.S. LLC | $42.18 | 2025 | |
| Bardy Diagnostics, INC. | $40.11 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $38.96 | 2022 | |
| Ironwood Pharmaceuticals, INC | $37.56 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $33.01 | 2019 | |
| Boston Scientific Corporation | $26.03 | 2025 | Watchman Access System |
| Atland Pharmaceuticals, LLC | $25.44 | 2025 | Tolmetin Sodium, Orphenadrine Citrate, Aspirin and Caffeine |
| Exact Sciences Corporation | $16.43 | 2025 | The Cologuard Plus Collection Kit |
| Eisai INC. | $15.07 | 2021 | |
| Medtronic, INC. | $12.63 | 2021 | |
| Arbor Pharmaceuticals, INC. | $12.61 | 2021 | |
| Phadia US INC. | $11.46 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vera Lafosse listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.